C-Reactive Protein and Breast Cancer: New Insights from Old Molecule

International Journal of Breast Cancer

Volumn 2015, Issue , 2015, Pages

  Asegaonkar, Shilpa Balaji ^a   Asegaonkar, Balaji Narayanrao ^b   Takalkar, Unmesh Vidyadhar ^b   Advani, Suresh ^b   Thorat, Anand Pandurang ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b United CIIGMA Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; SERUM AMYLOID A;

BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CARDIOTOXICITY; CHRONIC INFLAMMATION; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SURVIVAL PREDICTION;

EID: 84961704464     PISSN: 20903170     EISSN: 20903189     Source Type: Journal    
DOI: 10.1155/2015/145647     Document Type: Review

References (40)

1. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11, International Agency for Research on Cancer, Lyon, France, 2013, http://globocan. iarc. fr.
2. I. H. Abdulkareem, "A review on aetio-pathogenesis of breast cancer, " Journal of Genetic Syndromes & Gene Therapy, vol. 4, article 142, 2013.
3. D. Hanahan andR. A. Weinberg, "The hallmarks of cancer, " Cell, vol. 100, no. 1, pp. 57-70, 2000.
4. F. Balkwill and A. Mantovani, "Inflammation and cancer: back to Virchow?" The Lancet, vol. 357, no. 9255, pp. 539-545, 2001.
5. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, " Carcinogenesis, vol. 30, no. 7, pp. 1073-1081, 2009.
6. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation, " Nature, vol. 454, no. 7203, pp. 436-444, 2008.
7. K. H. Allin and B. G. Nordestgaard, "Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer, " Critical Reviews in Clinical Laboratory Sciences, vol. 48, no. 4, pp. 155-170, 2011.
8. C.-S. Wang and C.-F. Sun, "C-reactive protein and malignancy: clinico-pathological association and therapeutic implication, " Chang Gung Medical Journal, vol. 32, no. 5, pp. 471-482, 2009.
9. C. Siemes, L. E. Visser, J.-W. W. Coebergh et al., "C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study, " Journal of Clinical Oncology, vol. 24, no. 33, pp. 5216-5222, 2006.
10. L. Guo, S. Liu, S. Zhang et al., "C-reactive protein and risk of breast cancer: A systematic review and meta-analysis, " Scientific Reports, vol. 5, Article ID10508, 2015.
11. Y.-Z. Guo, L. Pan, C.-J. Du, D.-Q. Ren, and X.-M. Xie, "Association between C-reactive protein and risk of cancer: A metaanalysis of prospective cohort studies, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 1, pp. 243-248, 2013.
12. G. Wang, N. Li, L. Cao et al., "Association between the level of high sensitivity C-reactive protein and risk of breast cancer among non-diabetic females: A prospective study in Kailuan group, " Zhonghua Zhong Liu Za Zhi, vol. 36, no. 12, pp. 944-948, 2014.
13. G. Wang, N. Li, S. Chang et al., "Aprospective follow-upstudyof the relationship between C-reactive protein and human cancer risk in the Chinese kailuan female cohort, " Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 2, pp. 459-465, 2014.
14. T. Hong, A. Liu, D. Cai et al., "Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status, " Cancer Investigation, vol. 31, no. 4, pp. 279-285, 2013.
15. L. Dossus, A. Jimenez-Corona, I. Romieu et al., "C-reactive protein and postmenopausal breast cancer risk: results fromthe E3N cohort study, " Cancer Causes & Control, vol. 25, no. 4, pp. 533-539, 2014.
16. S. M. Zhang, J. Lin, N. R. Cook et al., "C-reactive protein and risk of breast cancer, " Journal of the National Cancer Institute, vol. 99, no. 11, pp. 890-894, 2007.
17. D. Il'yasova, L. H. Colbert, T. B. Harris et al., "Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort, " Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 10, pp. 2413-2418, 2005.
18. D. Trichopoulos, T. Psaltopoulou, P. Orfanos, A. Trichopoulou, and P. Boffetta, "Plasma C-reactive protein and risk of cancer: A prospective study from Greece, " Cancer Epidemiology, Biomarkers & Prevention, vol. 15, no. 2, pp. 381-384, 2006.
19. N. R. Cook, I.-M. Lee, J. M. Gaziano et al., "Low-dose aspirin in the primary prevention of cancer. The women's health study: A randomized controlled trial, " The Journal of the American Medical Association, vol. 294, no. 1, pp. 47-55, 2005.
20. J. A. Baron, "Epidemiology of non-steroidal anti-inflammatory drugs and cancer, " Progress in Experimental Tumor Research, vol. 37, pp. 1-24, 2003.
21. K. H. Allin, B. G. Nordestgaard, J. Zacho, A. Tybjrg-Hansen, and S. E. Bojesen, "C-reactive protein and the risk of cancer: A mendelian randomization study, " Journal of the National Cancer Institute, vol. 102, no. 3, pp. 202-206, 2010.
22. K. Heikkilä, S. Ebrahim, and D. A. Lawlor, "A systematic review of the association between circulating concentrations of C reactive protein and cancer, " Journal of Epidemiology and Community Health, vol. 61, no. 9, pp. 824-833, 2007.
23. H. Cha-Molstad, D. P. Young, I. Kushner, and D. Samols, "The interaction of C-Rel with C/EBPbeta enhances C/EBPbeta binding to the C-reactive protein gene promoter, " Molecular Immunology, vol. 44, no. 11, pp. 2933-2942, 2007.
24. A. Moon, E.-S. Kim, M. Bae et al., "Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPbb and potentiates breast cancer progression, "TheFASEB Journal, vol. 29, no. 1, supplement, p. 728. 12, 2015.
25. K. H. Allin, B. G. Nordestgaard, H. Flyger, and S. E. Bojesen, "Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: A cohort study, " Breast Cancer Research, vol. 13, no. 3, article R55, 2011.
26. B. L. Pierce, R. Ballard-Barbash, L. Bernstein et al., "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients, " Journal of Clinical Oncology, vol. 27, no. 21, pp. 3437-3444, 2009.
27. Y. Han, F. Mao, Y. Wu et al., "Prognostic role of C-reactive protein in breast cancer: A systematic reviewandmeta-analysis, " International Journal of Biological Markers, vol. 26, no. 4, pp. 209-215, 2011.
28. A. M. Al Murri, C. Wilson, A. Lannigan et al., "Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer, " British Journal of Cancer, vol. 96, pp. 891-895, 2011.
29. S. Asegaonkar, U. Takalkar, P. Kodlikeri, A. Pagdhune, V. Bonduliya, and A. Thorat, "Serum high sensitivity C-reactive protein in breast cancer patients, " International Journal of Research in Medical Sciences, vol. 2, no. 4, pp. 1408-1411, 2014.
30. J. Zacho, A. Tybjrg-Hansen, and B. G. Nordestgaard, "Creactive protein and all-cause mortality-the Copenhagen City Heart Study, " European Heart Journal, vol. 31, no. 13, pp. 1624-1632, 2010.
31. J. Vakkila and M. T. Lotze, "Inflammation and necrosis promote tumour progression and metastasis, " Nature Reviews Cancer, vol. 4, pp. 71-78, 2004.
32. I. Sicking, K. Edlund, E. Wesbuer et al., "Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients, " PLoS ONE, vol. 9, no. 10, Article ID e111306, 2014.
33. C. A. Thomson, P. A. Thompson, J. Wright-Bea, E. Nardi, G. R. Frey, and A. Stopeck, "Metabolic syndrome and elevated Creactive protein in breast cancer survivors on adjuvant hormone therapy, " Journal of Women's Health, vol. 18, no. 12, pp. 2041-2047, 2009.
34. B. L. Pierce, M. L. Neuhouser, M. H. Wener et al., "Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors, " Breast Cancer Research and Treatment, vol. 114, no. 1, pp. 155-167, 2009.
35. B. Ky, M. Putt, H. Sawaya et al., "Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab, " Journal of theAmericanCollege of Cardiology, vol. 63, no. 8, pp. 809-816, 2014.
36. A. A. Onitilo, J. M. Engel, R. V. Stankowski, H. Liang, R. L. Berg, and S. A. R. Doi, "High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: A pilot study, " Breast Cancer Research and Treatment, vol. 134, no. 1, pp. 291-298, 2012.
37. C. Gabay and I. Kushner, "Acute phase protein and other systemic responses to inflammation, "The New England Journal of Medicine, vol. 6, pp. 448-454, 1999.
38. A. Villaseñor, S. W. Flatt, C. Marinac, L. Natarajan, J. P. Pierce, and R. E. Patterson, "Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL Study, " Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 1, pp. 189-199, 2014.
39. P. Ravishankaran and R. Karunanithi, "Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients, " World Journal of Surgical Oncology, vol. 9, article 18, 2011.
40. I. J. Fidler, "The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited, " Nature Reviews Cancer, vol. 3, no. 6, pp. 453-458, 2003.